Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I subcutaneous RBM-007 in healthy Japanese male volunteers
jRCT2080225249Phase 1Completed
- Sponsor
- Ribomic Inc.
- Start
- Jun 2020
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of umedaptanib pegol (4 arms), sponsored by Ribomic Inc. Primary endpoints: Safety and tolerability of RBM-007 and Pharmacokinetics of RBM-007. Started Jun 2020; status: completed.
02
Drugs
umedaptanib pegol
Beyond the preview
Go deeper on jRCT2080225249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225249.